×

Missed OPT Congress This Year?

Missed this year's virtual event? Access content across all of this year's programs On-Demand. At your convenience, access archived presentations for On-Demand learning, from anywhere, at anytime.




Now A Virtual Event For 2020

In this period of uncertainty and change due to COVID-19, we have made some important and exciting updates to the way we connect. Our experienced staff have made huge strides to ensure that the virtual 2020 event offers an enriching new way to present, access, connect and explore with the oligonucleotide community.



Keynote Speakers

Brett Monia, PhD
CEO, Ionis Pharmaceuticals

Edward Kaye, MD
CEO, Stoke Therapeutics

Muthiah (Mano) Manoharan, PhD
Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals

Dmitry Samarsky, PhD
CTO, Sirnaomics

Ekkehard Leberer, PhD
Senior Director, R&D Alliance Management, Sanofi; Scientific Managing Director, COMPACT Consortium

Marvin Caruthers, PhD
Distinguished Professor, University of Colorado

Phil Baran, PhD
Professor, Department of Chemistry, Scripps Research

Jesse Faber
Senior Process Engineer III, ASO Process Engineering and Manufacturing, Biogen

Francis Ring

Francis Ring
Assistant Director, Manufacturing & Operations, Ionis Pharmaceuticals

Patrick Lu, PhD
President & CEO, Sirnaomics

Elena Feinstein, MD, PhD
CSO, Quark Pharmaceuticals

David Corey, PhD
Professor, Department of Pharmacology, UT Southwestern



With thanks to our Executive Advisory Board

Dmitry Samarsky, PhD
CTO, Sirnaomics

Muthiah (Mano) Manoharan, PhD
Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals

Arthur Levin, PhD
Executive Vice President, Research and Development, Avidity Biosciences

Lubo Nechev, PhD
Vice President Process and Analytical Sciences, Alnylam Pharmaceuticals

Ekkehard Leberer, PhD
Senior Director, R&D Alliance Management, Sanofi


5th Annual Oligonucleotide & Precision Therapeutics Congress: Join us this Fall

(Dates: October 19-21, 2020  Location: VIRTUAL)
Bringing together leading discovery scientists, developers, CMC experts, regulatory specialists and technology providers, OPT Congress provides a unique opportunity to discuss advances in next-generation oligonucleotide therapies throughout the drug development process. Attend in 2020 to optimize your drug design, delivery and performance, accelerate time to market and achieve commercial success. Based on the resounding success of last year’s inaugural 2-day program dedicated to Oligonucleotide CMC & Regulatory Strategies we will once again be adding this content to complement our established Oligonucleotide Discovery and Delivery conference.

65%
of Attendees
from Biotech
15%
of Attendees
from Pharma
130+
Unique
Organizations
10+
Hours of
Networking